Therapeutic RNA Splicing Modulation: Mechanisms, Clinical Applications, and Future Directions

Abstract

Therapeutic RNA splicing modulation represents a rapidly evolving frontier in medical science, offering targeted interventions for a variety of genetic and acquired diseases. By influencing pre-mRNA splicing, clinicians and researchers can potentially correct aberrant gene expression, restore protein function, and mitigate disease progression. This review comprehensively discusses the epidemiology, disease burden, pathophysiological mechanisms, clinically relevant risk factors, characteristic features, diagnostic considerations, current and emerging management strategies, and recent guideline recommendations surrounding RNA splicing modulation. We integrate recent evidence from clinical trials and translational research to inform practice and highlight future directions for therapeutic development.

Introduction

RNA splicing is a critical post-transcriptional process wherein non-coding introns are removed and exons are joined to form mature messenger RNA (mRNA). Aberrant splicing events are implicated in a wide spectrum of human diseases, notably neuromuscular, hematological, oncological, and metabolic disorders. Recent advances have enabled the development of therapeutics capable of modulating splicing outcomes, such as antisense oligonucleotides (ASOs), small molecules, and gene-editing approaches. The advent of these technologies signifies a paradigm shift in treating previously intractable genetic diseases, providing hope for precision medicine applications. The clinical translation of splicing modulation therapies necessitates a thorough understanding of underlying molecular mechanisms, disease epidemiology, and patient selection criteria.

Epidemiology / Disease Burden

Splicing defects contribute to the pathogenesis of diverse conditions, accounting for an estimated 15–60% of mutations in inherited diseases. Notable examples include spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), certain thalassemias, and various cancers. SMA, for instance, occurs in approximately 1 in 10,000 live births and is the leading genetic cause of infant mortality. In oncology, recurrent splicing factor mutations are observed in myelodysplastic syndromes and solid tumors, impacting both prognosis and therapeutic response. The global burden of splicing-related disorders underscores the urgent need for effective, mechanistically driven therapies.

Pathophysiology

Pre-mRNA splicing is orchestrated by the spliceosome, a complex of small nuclear ribonucleoproteins (snRNPs) and auxiliary factors. Mutations or dysregulation in cis-regulatory elements (e.g., splice sites, enhancers, silencers) or trans-acting splicing factors can result in exon skipping, intron retention, or cryptic splice site utilization. These aberrations may produce truncated, nonfunctional, or toxic proteins. For example, in SMA, a deficiency of survival motor neuron (SMN) protein arises due to alternative splicing of the SMN2 gene, while in DMD, exon deletions disrupt the reading frame of dystrophin mRNA. In cancer, altered splicing may promote oncogenic isoforms or facilitate immune escape. Therapeutic splicing modulation aims to restore normal splicing patterns or redirect aberrant splicing events to yield functional proteins.

Risk Factors

Genetic predisposition remains the primary risk factor for splicing-related diseases, with pathogenic variants affecting core splicing signals or regulatory motifs. Environmental factors, including drugs, toxins, and cellular stress, can influence splicing machinery and exacerbate disease phenotypes. Age-related decline in splicing factor expression and somatic mutations, particularly in hematologic malignancies, further contribute to disease risk. Comprehensive genetic screening and molecular diagnostics are essential for identifying at-risk individuals and informing therapeutic decisions.

Clinical Features

The clinical presentation of diseases amenable to splicing modulation is heterogeneous and disease-specific. In SMA, patients exhibit progressive muscle weakness, respiratory insufficiency, and motor developmental delays. DMD presents with muscle degeneration, loss of ambulation, and cardiopulmonary complications. Splicing mutations in hematologic diseases may manifest as cytopenias, dysplasia, or increased leukemia risk. Cancer-associated splicing alterations can drive tumor progression and metastatic behavior. Clinicians should maintain a high index of suspicion for splicing-related pathology in patients with atypical or unexplained clinical syndromes, particularly when supported by family history and molecular findings.

Diagnosis

Accurate diagnosis relies on a combination of clinical assessment, genetic testing, and advanced molecular techniques. Next-generation sequencing (NGS) platforms enable the detection of splice-site mutations and aberrant transcripts. RNA sequencing provides direct evaluation of splicing patterns and isoform abundance. Confirmatory studies, such as reverse transcription polymerase chain reaction (RT-PCR) and functional assays, may be utilized to characterize splicing outcomes. Early and precise diagnosis is critical for timely intervention and optimal therapeutic response, especially as splicing modulation therapies are often genotype-specific.

Treatment & Management

Therapeutic strategies for splicing modulation include antisense oligonucleotides (ASOs), small molecule modulators, and gene-editing technologies. ASOs, such as nusinersen for SMA and eteplirsen for DMD, bind target pre-mRNA sequences to promote exon inclusion or skipping, thereby restoring protein expression. Small molecules, exemplified by risdiplam in SMA, modulate spliceosome activity. Gene-editing approaches using CRISPR/Cas systems are under investigation to correct splicing mutations at the DNA level. Clinical management also encompasses supportive measures—physical therapy, respiratory support, and multidisciplinary care—tailored to the underlying disease and patient needs.

Recent Advances / Emerging Therapies

Recent years have witnessed the regulatory approval of multiple splicing modulators, expanding the therapeutic landscape. Nusinersen and risdiplam have transformed SMA outcomes, enabling improved motor function and survival. Clinical trials are exploring next-generation ASOs and oral agents targeting diverse splicing events in neuromuscular, hematologic, and oncologic diseases. Additionally, advances in delivery systems, such as lipid nanoparticles and viral vectors, enhance tissue specificity and bioavailability. Personalized medicine approaches leveraging transcriptomic profiling and biomarker-driven patient selection are poised to optimize efficacy and minimize adverse effects. Despite these advances, challenges persist regarding long-term safety, immunogenicity, and off-target effects.

Guideline Recommendations

International guidelines increasingly recognize the role of splicing modulation in disease management. For example, consensus statements from neurology and genetics societies endorse early initiation of ASO therapy in SMA, with regular monitoring of motor milestones and respiratory function. Genetic confirmation of splicing mutations is recommended prior to therapy initiation. In oncology, molecular subtyping—including splicing factor profiling—informs prognostication and therapeutic selection. Multidisciplinary collaboration, patient education, and pharmacovigilance are emphasized to optimize clinical outcomes and safety.

Conclusion

Therapeutic RNA splicing modulation stands at the forefront of precision medicine, offering novel solutions for diseases once deemed untreatable. Integrating mechanistic insights, robust diagnostics, and emerging therapeutics is essential for realizing the full potential of this approach. Ongoing research, guideline evolution, and clinical experience will shape the future trajectory of splicing modulation, ultimately improving patient care across diverse medical disciplines.